IDEAS home Printed from https://ideas.repec.org/p/nbr/nberwo/26356.html
   My bibliography  Save this paper

How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs

Author

Listed:
  • Thuy D. Nguyen
  • W. David Bradford
  • Kosali I. Simon

Abstract

Prior work considers effects of prescribing restrictions on opioid use but not upstream implications for pharmaceutical marketing activities, despite the inordinate role many believe marketing played in the crisis. Our study proposes a stylized model of pharmaceutical payments and investigates the impact of Mandatory Access Prescription Drug Monitoring Programs (MPDMPs) on opioid-specific commercial promotion directed at physicians. We find that MPDMPs reduce promotion on both extensive and intensive margins. Our results are consistent with economic theory, predicting lower promotional activities when return on investment decreases after state prescribing restrictions, and indicative of MPDMPs' role in affecting opioid use through reduced promotion.

Suggested Citation

  • Thuy D. Nguyen & W. David Bradford & Kosali I. Simon, 2019. "How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs," NBER Working Papers 26356, National Bureau of Economic Research, Inc.
    • Handle: RePEc:nbr:nberwo:26356
    Note: HC HE
    as

    Download full text from publisher

    File URL: http://www.nber.org/papers/w26356.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. repec:aph:ajpbhl:10.2105/ajph.2017.303982_3 is not listed on IDEAS
    2. Stigler, George J., 2011. "Economics of Information," Economic Policy, Russian Presidential Academy of National Economy and Public Administration, vol. 5, pages 35-49.
    3. Abby Alpert & David Powell & Rosalie Liccardo Pacula, 2018. "Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids," American Economic Journal: Economic Policy, American Economic Association, vol. 10(4), pages 1-35, November.
    4. Angélica Meinhofer, 2018. "Prescription Drug Monitoring Programs: The Role of Asymmetric Information on Drug Availability and Abuse," American Journal of Health Economics, University of Chicago Press, vol. 4(4), pages 504-526, Fall.
    5. Lakdawalla, Darius & Sood, Neeraj & Gu, Qian, 2013. "Pharmaceutical advertising and Medicare Part D," Journal of Health Economics, Elsevier, vol. 32(6), pages 1356-1367.
    6. Dhaval Dave & Monica Deza & Brady P. Horn, 2018. "Prescription Drug Monitoring Programs, Opioid Abuse, and Crime," NBER Working Papers 24975, National Bureau of Economic Research, Inc.
    7. Daniel W. Sacks & Alex Hollingsworth & Thuy D. Nguyen & Kosali I. Simon, 2019. "Can Policy Affect Initiation of Addictive Substance Use? Evidence from Opioid Prescribing," NBER Working Papers 25974, National Bureau of Economic Research, Inc.
    8. Keyes, K.M. & Cerdá, M. & Brady, J.E. & Havens, J.R. & Galea, S., 2014. "Understanding the rural-urban differences in nonmedical prescription opioid use and abuse in the United States," American Journal of Public Health, American Public Health Association, vol. 104(2), pages 52-59.
    9. William N. Evans & Ethan M. J. Lieber & Patrick Power, 2019. "How the Reformulation of OxyContin Ignited the Heroin Epidemic," The Review of Economics and Statistics, MIT Press, vol. 101(1), pages 1-15, March.
    10. Hadland, S.E. & Krieger, M.S. & Marshall, B.D.L., 2017. "Industry payments to physicians for opioid products, 2013-2015," American Journal of Public Health, American Public Health Association, vol. 107(9), pages 1493-1495.
    11. Van Zee, A., 2009. "The promotion and marketing of oxycontin: Commercial triumph, public health tragedy," American Journal of Public Health, American Public Health Association, vol. 99(2), pages 221-227.
    12. Rosalie Liccardo Pacula & David Powell, 2018. "A Supply‐Side Perspective On The Opioid Crisis," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 37(2), pages 438-446, March.
    13. Colleen Carey & Ethan M.J. Lieber & Sarah Miller, 2020. "Drug Firms' Payments and Physicians' Prescribing Behavior in Medicare Part D," NBER Working Papers 26751, National Bureau of Economic Research, Inc.
    14. Thomas C. Buchmueller & Colleen Carey, 2018. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," American Economic Journal: Economic Policy, American Economic Association, vol. 10(1), pages 77-112, February.
    15. Angélica Meinhofer, 2018. "Prescription Drug Monitoring Programs: The Role of Asymmetric Information on Drug Availability and Abuse," American Journal of Health Economics, MIT Press, vol. 4(4), pages 504-526, Fall.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sumedha Gupta & Thuy D. Nguyen & Patricia R. Freeman & Kosali I. Simon, 2020. "Competitive Effects of Federal and State Opioid Restrictions: Evidence from the Controlled Substance Laws," NBER Working Papers 27520, National Bureau of Economic Research, Inc.
    2. Casey B. Mulligan, 2020. "Prices and Federal Policies in Opioid Markets," Working Papers 2020-10, Becker Friedman Institute for Research In Economics.
    3. Casey B. Mulligan, 2020. "Prices and Federal Policies in Opioid Markets," NBER Working Papers 26812, National Bureau of Economic Research, Inc.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Janssen, Aljoscha & Zhang, Xuan, 2020. "Retail Pharmacies and Drug Diversion during the Opioid Epidemic," Working Paper Series 1373, Research Institute of Industrial Economics.
    2. Kim, Bokyung, 2021. "Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences," Journal of Health Economics, Elsevier, vol. 75(C).
    3. David Powell & Rosalie Liccardo Pacula, 2021. "The Evolving Consequences of OxyContin Reformulation on Drug Overdoses," American Journal of Health Economics, University of Chicago Press, vol. 7(1), pages 41-67.
    4. Daniel W. Sacks & Alex Hollingsworth & Thuy D. Nguyen & Kosali I. Simon, 2019. "Can Policy Affect Initiation of Addictive Substance Use? Evidence from Opioid Prescribing," NBER Working Papers 25974, National Bureau of Economic Research, Inc.
    5. Thomas C. Buchmueller & Colleen M. Carey & Giacomo Meille, 2020. "How well do doctors know their patients? Evidence from a mandatory access prescription drug monitoring program," Health Economics, John Wiley & Sons, Ltd., vol. 29(9), pages 957-974, September.
    6. Sumedha Gupta & Thuy D. Nguyen & Patricia R. Freeman & Kosali I. Simon, 2020. "Competitive Effects of Federal and State Opioid Restrictions: Evidence from the Controlled Substance Laws," NBER Working Papers 27520, National Bureau of Economic Research, Inc.
    7. Deiana, Claudio & Giua, Ludovica, 2018. "The US Opidemic: Prescription Opioids, Labour Market Conditions and Crime," MPRA Paper 85712, University Library of Munich, Germany.
    8. Cotti, Chad D. & Gordanier, John M. & Ozturk, Orgul D., 2020. "The relationship of opioid prescriptions and the educational performance of children," Social Science & Medicine, Elsevier, vol. 265(C).
    9. Casey B. Mulligan, 2020. "Prices and Federal Policies in Opioid Markets," Working Papers 2020-10, Becker Friedman Institute for Research In Economics.
    10. Casey B. Mulligan, 2020. "Prices and Federal Policies in Opioid Markets," NBER Working Papers 26812, National Bureau of Economic Research, Inc.
    11. Thomas C. Buchmueller & Colleen M. Carey & Giacomo Meille, 2019. "How Well Do Doctors Know Their Patients? Evidence from a Mandatory Access Prescription Drug Monitoring Program," NBER Working Papers 26159, National Bureau of Economic Research, Inc.
    12. Christopher J. Ruhm, 2019. "Shackling the Identification Police?," Southern Economic Journal, John Wiley & Sons, vol. 85(4), pages 1016-1026, April.
    13. Gihleb, Rania & Giuntella, Osea & Zhang, Ning, 2019. "Prescription Drug Monitoring Programs and Neonatal Outcomes," IZA Discussion Papers 12796, Institute of Labor Economics (IZA).
    14. Borgschulte, Mark & Corredor-Waldron, Adriana & Marshall, Guillermo, 2018. "A path out: Prescription drug abuse, treatment, and suicide," Journal of Economic Behavior & Organization, Elsevier, vol. 149(C), pages 169-184.
    15. Dionissi Aliprantis & Mark E. Schweitzer, 2018. "Opioids and the Labor Market," Working Papers (Old Series) 1807, Federal Reserve Bank of Cleveland.
    16. Ahammer, Alexander & Halla, Martin, 2020. "The Intergenerational Transmission of Opioid Dependence: Evidence from Administrative Data," IZA Discussion Papers 13395, Institute of Labor Economics (IZA).
    17. David Beheshti, 2019. "Adverse health effects of abuse‐deterrent opioids: Evidence from the reformulation of OxyContin," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1449-1461, December.
    18. Gihleb, Rania & Giuntella, Osea & Zhang, Ning, 2020. "Prescription drug monitoring programs and neonatal outcomes," Regional Science and Urban Economics, Elsevier, vol. 81(C).
    19. Alexander Ahammer, 2019. "A novel supply-side measure to combat abuse of addictive prescription drugs," Economics working papers 2019-11, Department of Economics, Johannes Kepler University Linz, Austria.
    20. Park, Sujeong & Powell, David, 2021. "Is the rise in illicit opioids affecting labor supply and disability claiming rates?," Journal of Health Economics, Elsevier, vol. 76(C).

    More about this item

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:26356. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (). General contact details of provider: https://edirc.repec.org/data/nberrus.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.